Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 168
- Registration Number
- NCT05846789
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 34
- Registration Number
- NCT04134884
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 18
- Registration Number
- NCT03243331
- Locations
- 🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 42
- Registration Number
- NCT02595372
- Locations
- 🇺🇸
Indiana University Health North Hospital, Carmel, Indiana, United States
🇺🇸Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 11
- Registration Number
- NCT02575339
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
Impact of LOFT Therapyâ„¢ on Breast Cancer Survivors
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 15
- Registration Number
- NCT02491957
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Hospital, Indianapolis, Indiana, United States
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 4
- Registration Number
- NCT02443103
- Locations
- 🇺🇸
Sidney & Lois Eskenazi Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 10
- Registration Number
- NCT00827372
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States